Pharmacological and clinical evaluation of venetoclax-BCL-2 inhibitor in the treatment of chronic lymphocytic leukemia
WANG Xue-yang
FENG Yu-fei
HU Xin
Abstract：Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2.It is mainly indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion,who have received at least one prior therapy.The most common adverse events were diarrhea,nausea,upper respiratory tract infection,neutropenia,and fatigue.The pharmacology,pharmacokinetics,clinical research,safety,dosage,and drug interactions of venetoclax were reviewed in this paper.
Keywords：venetoclaxchronic lymphocytic leukemiaB-cell lymphoma factor 2 (BCL-2) inhibitorpharmacologyclinical evaluation
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 1473-1476 )